Quantum Diamond Technologies Inc.
Quantum Diamond Technologies develops NV-diamond quantum sensing instruments for biomarker detection in biomedical research, drug discovery, and diagnostics.
- Category
- Quantum sensing
- Technology
- NV-center diamond quantum sensing for magnetic biomarker detection
- Ownership
- Private company
- Funding
- The company website states QDTI received a $500K Phase III START grant (July 1, 2020), a Michael J. Fox Foundation grant to develop biomarker assays for Parkinson’s disease (June 1, 2019; amount not stated), and a $100k MassVentures START Program award (July 1, 2018).
- Products and platforms
- QDTI imaging platform, Magnetic-based Immunoassay Detection
- Key people
- Colin Connolly, CEO, CTO, QDTI Co-founder
Jason Cleveland, Board Chairman
Jeff Krogmeier, COO, Engineering
Mikhail Lukin, Scientific Advisor, Co-founder, Board Member - Website
- qdti.com
Quantum Diamond Technologies Inc. says it applies quantum sensing to biomarker detection for biomedical research, drug discovery and development, and diagnostic testing. Its platform is based on nitrogen vacancy (NV) centers in synthetic diamond sensors, drawing on research at Harvard University.
According to the company, its instrument uses billions of NV centers near the diamond surface to image magnetic fields and supports an all-magnetic immunoassay detection approach. The website describes the platform as capable of detecting proteins, nucleic acids, and cells, with applications spanning neurology, cardiovascular disease, immuno-oncology, inflammation-related disorders, and infectious diseases.
The company website also lists grants and awards, including a $500,000 Phase III START grant announced in July 2020, a Michael J. Fox Foundation grant announced in June 2019 to develop Parkinson's disease biomarker assays, and a $100,000 MassVentures START Program award announced in July 2018.
Sources
Facts on this page come from the sources below, retrieved by DesignQuantum.
Last verified: October 28, 2026